作者:Amantullah Ansari、Sharad Satalkar、Varshavekumar Patil、Amit S. Shete、Simranjeet Kaur、Ashu Gupta、Siddhartha Singh、Mohd. Raja、Daniel L. Severance、Sebastián Bernales、Sarvajit Chakravarty、David T. Hung、Son M. Pham、Francisco J. Herrera、Roopa Rai
DOI:10.1016/j.bmcl.2016.11.080
日期:2017.1
cancers and therefore EZH2 inhibition has emerged as a promising therapeutic target. Several small molecule EZH2 inhibitors with different chemotypes have been reported in the literature, many of which use a bicyclic heteroaryl core. Herein, we report the design and synthesis of EZH2 inhibitors containing an indoline core. Partial saturation of an indole to an indoline provided lead compounds with nanomolar
EZH2(zeste同源物2的增强剂)是多梳抑制复合物2(PRC2)的催化亚基,它催化组蛋白H3(H3K27)的赖氨酸27的甲基化。EZH2活性的失调与几种人类癌症有关,因此EZH2抑制已成为有希望的治疗靶点。文献中已经报道了几种具有不同化学型的小分子EZH2抑制剂,其中许多使用双环杂芳基核心。在本文中,我们报告了包含吲哚啉核心的EZH2抑制剂的设计和合成。吲哚对吲哚的部分饱和为铅化合物提供了针对EZH2的纳摩尔活性,同时还提高了溶解度和氧化代谢稳定性。